On June 17, Alibaba Health fell 3.21% in regular trading, trading at HKD 3.32/share, with turnover of HKD 138 million. The decline was driven by a combination of macro liquidity concerns and company-specific dilution effects.
On the macro front, persistent global liquidity tightening signals have weighed on Hong Kong-listed technology and healthcare stocks, with analysts forecasting that the Fed's next policy move could be a rate hike. On June 15, the company announced the grant of 56.4645 million restricted share units to 521 grantees and 2.2835 million share options under its share award plan, raising market concerns over potential equity dilution.
Within the Internet and Direct Marketing Retail sector, the overall tone remained weak. Among peers, JD Health fell 3.0%, PA Good Doctor fell 3.17%, Meituan fell 1.93%, JD-SW fell 0.99%, and BABA-W fell 0.84%, reflecting broad-based sector pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments